(Q36612331)

English

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.

scientific article published on 3 October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Christian von Plessen

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

author name string

B Bergman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

O Andresen

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

R M Bremnes

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

S Sundstrom

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

M Gilleryd

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

R Stephens

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

J Vilsvik

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

U Aasebo

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

S Sorenson

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

language of work or name

0 references

publication date

3 October 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

British Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

95

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

966-973

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6603383

0 references

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Patients preferences in chemotherapy for advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Chemotherapy and radiotherapy. When to call it quits.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Carboplatin plus vinorelbine, a new well-tolerated and active regimen for the treatment of extensive-stage small-cell lung cancer: a phase II study. Gruppo Oncologico Centro-Sud-Isole

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Cancer patients, doctors and nurses vary in their willingness to undertake cancer chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Current issues in the design and interpretation of clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

30 September 2017

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

28 June 2018

Improving the quality of palliative care for ambulatory patients with lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Direct treatment costs for patients with lung cancer from first recurrence to death in france.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Chemotherapy Use among Medicare Beneficiaries at the End of Life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Participation of patients 65 years of age or older in cancer clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study G

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360695

20 September 2018

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603383

21 January 2018

Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and toxicity of vinorelbine-carboplatin combination in the treatment of advanced adenocarcinoma or large-cell carcinoma of the lung

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin and vinorelbine in advanced non-small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin and vinorelbine in the treatment of advanced non-small-cell lung cancer: a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Participation in cancer clinical trials: race-, sex-, and age-based disparities

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17047644

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6603383

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17047644%20AND%20SRC:MED&resulttype=core&format=json

20 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36612331&oldid=2104176442"